Literature DB >> 2421954

Activation of cytotoxic T cells and effector cells in experimental autoimmune thyroiditis by shared determinants of mouse and human thyroglobulins.

L L Simon, J M Justen, A A Giraldo, C J Krco, Y C Kong.   

Abstract

Previous studies have shown that T cells from genetically susceptible mice developing experimental autoimmune thyroiditis (EAT) proliferate in response to restimulation with mouse thyroglobulin (MTg) in vitro and differentiate into cells cytotoxic for syngeneic thyroid monolayers. To examine further the effector cells involved in pathogenesis and the determinants on MTg responsible for their activation, spleen cells (SC) and lymph node cells (LNC) from mice immunized with MTg or human (H) Tg, and adjuvant (complete Freund's adjuvant (CFA) or lipopolysaccharide (LPS] were cultured in vitro with MTg or HTg. Control cultures were incubated with concanavalin A (Con A) or purified protein derivative (PPD). The in vitro-activated cells which proliferated in response to MTg, HTg, or Con A adoptively transferred thyroiditis to normal recipients, whereas cells transferred directly without in vitro culture were very ineffective. The capacity to transfer EAT was abrogated by irradiation (1500 R), and SC from CFA-immunized control mice which responded in vitro to PPD stimulation did not transfer thyroiditis. The serum titers of MTg autoantibodies were uniformly low and were not correlated with severity of disease. The localization of EAT-effector (precursor) cells depended upon the site of immunization; they were found in the spleens after inguinal (subcutaneous) or systemic (intravenous) immunizations, but were present in the popliteal lymph nodes after hind footpad injections. Both homologous MTg and heterologous HTg functioned as in vivo sensitizing antigen and in vitro activating antigen for each other; such cultured cells transferred thyroiditis in vivo and became cytotoxic for thyroid monolayers in vitro. These findings show that shared determinants are autoantigenic and thyroiditogenic, and support the hypothesis that EAT-effector cells responsible for initiating thyroid damage include cytotoxic cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421954     DOI: 10.1016/0090-1229(86)90098-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

Review 1.  Thyroglobulin as autoantigen: structure-function relationships.

Authors:  M Vali; N R Rose; P Caturegli
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

2.  Recognition of thyroglobulin autoantigenic epitopes by murine T and B cells.

Authors:  B R Champion; K Page; D C Rayner; R Quartey-Papafio; P G Byfield; G Henderson
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

Review 3.  T cell-mediated mechanisms in autoimmune thyroiditis.

Authors:  G W Canonica; M Bagnasco; Y M Kong
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

4.  Severe combined immunodeficient (SCID) mice: a model for investigating human thyroid autoantibody synthesis.

Authors:  L Macht; N Fukuma; K Leader; D Sarsero; C A Pegg; D I Phillips; P Yates; S M McLachlan; C Elson; B Rees Smith
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

5.  Superiority of thyroid peroxidase DNA over protein immunization in replicating human thyroid autoimmunity in HLA-DRB1*0301 (DR3) transgenic mice.

Authors:  J C Flynn; A Gardas; Q Wan; M Gora; G Alsharabi; W Z Wei; A A Giraldo; C S David; Y M Kong; J P Banga
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 6.  Thyroglobulin as an autoantigen: what can we learn about immunopathogenicity from the correlation of antigenic properties with protein structure?

Authors:  Fabrizio Gentile; Marisa Conte; Silvestro Formisano
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

7.  A thyroxine-containing peptide can induce murine experimental autoimmune thyroiditis.

Authors:  P R Hutchings; A Cooke; K Dawe; B R Champion; M Geysen; R Valerio; I M Roitt
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.